PMID- 34873532
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211208
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 13
IP  - 11
DP  - 2021 Nov
TI  - Comparison of Efficacy of Ivabradine With Traditional Therapy in Patients With 
      Left Ventricular Dysfunction.
PG  - e19192
LID - 10.7759/cureus.19192 [doi]
LID - e19192
AB  - BACKGROUND: Heart failure patients usually present with disease exacerbation that 
      overburdens the hospitals and also increases the risk of mortality with increased 
      heart rate being the main issue. Consideration is being given to drugs for sole 
      heart rate control in addition to conventional therapy. OBJECTIVE: To compare the 
      outcomes of ivabradine to traditional treatment in patients with left ventricular 
      systolic dysfunction. METHODOLOGY: This randomized controlled trial was conducted 
      in the Department of Cardiology, Khyber Teaching Hospital, Peshawar from November 
      1, 2020, to May 31, 2021. Patients aged 30-65 years of age and of either gender 
      with heart failure were enrolled in the study. Patients were screened for New 
      York Heart Association (NYHA) class and were enrolled into one of the two groups. 
      In group 1, patients were started on traditional treatment, while group 2 
      patients were given ivabradine as an add-on therapy. Follow-up was made at the 
      end of the second month for evaluation of the outcomes. RESULTS: Each group had 
      119 patients, with a mean age of 58.05+/-4.98 years. Group 1, consisted of 61.3% of 
      the patients in NYHA 3, while 38.65% were in NYHA 4. In group 2, NYHA 3 and NYHA 
      4 patients were 59.6% and 40.3%, respectively. Upon follow-up, there were 
      greater improvements in group 2 as compared to group 1 based on NYHA 
      classifications, with NYHA 2 [47.05% (group 2) vs. 13.44% (group 1)], NYHA 3 
      [42.85% (group 2) vs. 61.34% (group 1)] and NYHA 4 [10.08% (group 2) vs. 25.21% 
      (group 1)], p < 0.05. CONCLUSIONS: Obtaining a more optimal heart rate with 
      ivabradine in patients with congestive heart failure is reflected in an 
      improvement in NYHA classification.
CI  - Copyright (c) 2021, Ali et al.
FAU - Ali, Umair
AU  - Ali U
AD  - Cardiology, Khyber Teaching Hospital Peshawar Pakistan, Peshawar, PAK.
FAU - Ahmad, Tanveer
AU  - Ahmad T
AD  - Cardiology Department, Qazi Hussain Ahmed Medical Complex, Nowshera, PAK.
FAU - Khan, Jehanzeb
AU  - Khan J
AD  - Cardiology, Lady Reading Hospital, Peshawar, PAK.
AD  - Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, London, GBR.
FAU - Khan, Muhammad Ijaz
AU  - Khan MI
AD  - Medicine Unit, Khyber Teaching Hospital, Peshawar, PAK.
AD  - Internal Medicine, University Hospital, Tralee, IRL.
FAU - Khan, Hurriya
AU  - Khan H
AD  - Medicine, Khyber Medical College, Peshawar, PAK.
FAU - Javed, Bilal
AU  - Javed B
AD  - Medicine, Quaideazam Medical College, Bahawalpur, PAK.
LA  - eng
PT  - Journal Article
DEP - 20211101
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC8635682
OTO - NOTNLM
OT  - congestive heart failure
OT  - ivabradine
OT  - nyha class
OT  - re-admissions
OT  - traditional therapy
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/12/08 06:00
MHDA- 2021/12/08 06:01
PMCR- 2021/11/01
CRDT- 2021/12/07 06:45
PHST- 2021/11/01 00:00 [accepted]
PHST- 2021/12/07 06:45 [entrez]
PHST- 2021/12/08 06:00 [pubmed]
PHST- 2021/12/08 06:01 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - 10.7759/cureus.19192 [doi]
PST - epublish
SO  - Cureus. 2021 Nov 1;13(11):e19192. doi: 10.7759/cureus.19192. eCollection 2021 
      Nov.